Radioembolization for Liver Cancer with Vein Involvement
Part of Cancer, Digestive system clinical trials.
This trial tests a targeted radiation treatment (radioembolization) for liver cancer that has grown into the main vein (portal vein) but is still limited to one lobe of the liver. It is for people who have not received any prior cancer treatment and whose liver function is still fairly good.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your liver cancer is in one lobe and has not spread to other parts of the body.
- You have not had any previous treatment for liver cancer.
- Your liver function is good (Child-Pugh class A, meaning mild liver disease).
- You are generally healthy enough to do light daily activities (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining radiation therapy (radioembolization) with surgery to remove part of the liver for people with a single large liver tumor (over 8 cm) that hasn't spread. The goal is to see if this approach can treat the tumor effectively.
This trial tests a treatment called yttrium-90 carbon microsphere radioembolization for people with liver cancer that has been previously treated. Tiny radioactive beads are delivered directly to the tumor through the blood vessels to destroy cancer cells from inside. This may be an option if your liver cancer has not spread beyond the liver and you can tolerate the procedure.
This trial tests a combination of moderate-dose radiation therapy and the immunotherapy drug pembrolizumab (Keytruda) for liver cancer that has spread into the main veins of the liver. It aims to see if this combination can shrink tumors and improve survival.
This trial tests whether combining radiation (IMRT) with two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—before surgery can help people with liver cancer that has spread to the main blood vessel of the liver (portal vein). The goal is to shrink the tumor and improve surgical outcomes.
This trial tests a treatment called radioembolization for small liver cancers. Radioembolization delivers tiny radioactive beads to the tumor, and the goal is to see if it helps shrink or control the cancer.
This trial tests adding radiation (SBRT) to a combination of immunotherapy drugs (atezolizumab and bevacizumab) for people with liver cancer that has spread into the main portal vein. It aims to see if this approach can shrink tumors and improve outcomes.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.